Nanotechnology Now - Press Release: AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

Home > Press > AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO, will present an overview of the Company at two upcoming healthcare conferences.

AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences

Cambridge, MA | Posted on January 23rd, 2008

Dr. Pereira will present at the 2008 Wachovia Healthcare Conference in Boston on Wednesday, January 30, 2008 at 9:30 a.m. ET and at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York on February 6 at 1:00 p.m. ET.

Live audio webcasts of these presentations will be accessible through the Investors section of the Company's web site at www.amagpharma.com. Following the conferences, audio webcasts will be archived on the AMAG Pharmaceuticals, Inc. web site for approximately two weeks.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in patients with CKD. The Company has released data on all four of its planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in patients with CKD. The Company filed a New Drug Application for ferumoxytol with the U.S. FDA in December 2007.

Combidex®, the Company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, AMAG Pharmaceuticals, Inc. received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: